Documents disponibles écrits par cet auteur

Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand / Nicholas BOWDEN in Autism, 24-8 (November 2020) 

Public ISBD [article]  in Autism > 24-8 (November 2020) . - p.2213-2227 Titre : Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand Type de document : texte imprimé Auteurs : Nicholas BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Richard AUDAS, Auteur ; Barry MILNE, Auteur ; Kirsten SMILER, Auteur ; Hilary STACE, Auteur ; Barry TAYLOR, Auteur ; Sheree GIBB, Auteur Article en page(s) : p.2213-2227 Langues : Anglais (eng) Mots-clés : *Integrated Data Infrastructure  *autism spectrum disorder  *big data  *case identification  *mental health Index. décimale : PER Périodiques Résumé : New Zealand has few estimates of the prevalence autism spectrum disorder and no national registry or data set to identify and track cases. This hinders the ability to make informed, evidence-based decisions relating to autism spectrum disorder. In this study, we utilised linked health and non-health data to develop a method for identifying cases of autism spectrum disorder among children and young people in New Zealand. In addition, we examined rates of co-occurring mental health, neurodevelopmental and related conditions among this cohort and compared these to the general population. The method identified almost 10,000 children and young people with autism spectrum disorder in New Zealand. Co-occurring mental health or related problems were found in over 68% of this group (nearly seven times higher than the general population), and around half were identified with multiple co-occurring conditions. The most frequently identified conditions were intellectual disability, disruptive behaviours and emotional problems. We have developed a useful method for monitoring service and treatment-related trends, number and types of co-occurring conditions and examining social outcomes among individuals with autism spectrum disorder. While the method may underestimate the prevalence of autism spectrum disorder in New Zealand, it provides a significant step towards establishing a more comprehensive evidence base to inform autism spectrum disorder-related policy. En ligne : http://dx.doi.org/10.1177/1362361320939329 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4319 [article] Autism spectrum disorder/Takiw?tanga: An Integrated Data Infrastructure-based approach to autism spectrum disorder research in New Zealand [texte imprimé] / Nicholas BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Richard AUDAS, Auteur ; Barry MILNE, Auteur ; Kirsten SMILER, Auteur ; Hilary STACE, Auteur ; Barry TAYLOR, Auteur ; Sheree GIBB, Auteur . - p.2213-2227. Langues : Anglais (eng) in Autism > 24-8 (November 2020) . - p.2213-2227 Mots-clés : *Integrated Data Infrastructure  *autism spectrum disorder  *big data  *case identification  *mental health Index. décimale : PER Périodiques Résumé : New Zealand has few estimates of the prevalence autism spectrum disorder and no national registry or data set to identify and track cases. This hinders the ability to make informed, evidence-based decisions relating to autism spectrum disorder. In this study, we utilised linked health and non-health data to develop a method for identifying cases of autism spectrum disorder among children and young people in New Zealand. In addition, we examined rates of co-occurring mental health, neurodevelopmental and related conditions among this cohort and compared these to the general population. The method identified almost 10,000 children and young people with autism spectrum disorder in New Zealand. Co-occurring mental health or related problems were found in over 68% of this group (nearly seven times higher than the general population), and around half were identified with multiple co-occurring conditions. The most frequently identified conditions were intellectual disability, disruptive behaviours and emotional problems. We have developed a useful method for monitoring service and treatment-related trends, number and types of co-occurring conditions and examining social outcomes among individuals with autism spectrum disorder. While the method may underestimate the prevalence of autism spectrum disorder in New Zealand, it provides a significant step towards establishing a more comprehensive evidence base to inform autism spectrum disorder-related policy. En ligne : http://dx.doi.org/10.1177/1362361320939329 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4319

Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder / Hiran THABREW in Research in Autism Spectrum Disorders, 74 (June 2020) 

Public ISBD [article]  in Research in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Titre : Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder Type de document : texte imprimé Auteurs : Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur Article en page(s) : p.101553 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4229 [article] Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder [texte imprimé] / Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur . - p.101553. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4229

National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder / Nicholas BOWDEN in Research in Autism Spectrum Disorders, 78 (October 2020) 

Public ISBD [article]  in Research in Autism Spectrum Disorders > 78 (October 2020) . - 101642 Titre : National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder Type de document : texte imprimé Auteurs : Nicholas BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Rhiannon BRAUND, Auteur Article en page(s) : 101642 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Children  Adolescents  Pharmacotherapy  Integrated Data Infrastructure  Polypharmacy Index. décimale : PER Périodiques Résumé : Background International data and guidance on prescribing for children and young people with autism spectrum disorder (ASD) are limited. National administrative datasets such as the New Zealand Integrated Data Infrastructure (IDI) may offer a cost-effective and sustainable way to monitor prescribing trends in the context of clinical and systemic change. Method Medication dispensing for New Zealand children and young people with ASD was explored using the IDI. Psychotropic and non-psychotropic medication dispensing rates, and rates of polypharmacy within a one-year period were examined. Comparisons of medication use were made to children and young people with another neurodevelopmental condition, attention deficit hyperactivity disorder (ADHD), and the general population. Results The vast majority (83 %) of children and young people with ASD were prescribed medication within a one-year period and they received a mean of four unique medications. High dispensing of antihistamine, asthma, gastrointestinal, and psychotropic medications was observed. Just over half (57 %) of those with ASD experienced polypharmacy of three or more medications, and 11 % of 10 or more. Medication dispensing rates were significantly higher among the ASD group compared to those with ADHD and the general population. Polypharmacy rates were higher among both the ASD and ADHD group compared to the general population. Conclusions It is clear that New Zealand children and young people with ASD experience a significant and disproportionate medication burden. Although further investigation is needed to fully understand underlying reasons and clinical implications, the IDI appears to be a valuable means of monitoring prescribing trends over time. En ligne : https://doi.org/10.1016/j.rasd.2020.101642 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4331 [article] National prescribing rates and polypharmacy for children and young people in New Zealand with and without autism spectrum disorder [texte imprimé] / Nicholas BOWDEN, Auteur ; Hiran THABREW, Auteur ; Jesse KOKAUA, Auteur ; Rhiannon BRAUND, Auteur . - 101642. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 78 (October 2020) . - 101642 Mots-clés : Autism spectrum disorder  Children  Adolescents  Pharmacotherapy  Integrated Data Infrastructure  Polypharmacy Index. décimale : PER Périodiques Résumé : Background International data and guidance on prescribing for children and young people with autism spectrum disorder (ASD) are limited. National administrative datasets such as the New Zealand Integrated Data Infrastructure (IDI) may offer a cost-effective and sustainable way to monitor prescribing trends in the context of clinical and systemic change. Method Medication dispensing for New Zealand children and young people with ASD was explored using the IDI. Psychotropic and non-psychotropic medication dispensing rates, and rates of polypharmacy within a one-year period were examined. Comparisons of medication use were made to children and young people with another neurodevelopmental condition, attention deficit hyperactivity disorder (ADHD), and the general population. Results The vast majority (83 %) of children and young people with ASD were prescribed medication within a one-year period and they received a mean of four unique medications. High dispensing of antihistamine, asthma, gastrointestinal, and psychotropic medications was observed. Just over half (57 %) of those with ASD experienced polypharmacy of three or more medications, and 11 % of 10 or more. Medication dispensing rates were significantly higher among the ASD group compared to those with ADHD and the general population. Polypharmacy rates were higher among both the ASD and ADHD group compared to the general population. Conclusions It is clear that New Zealand children and young people with ASD experience a significant and disproportionate medication burden. Although further investigation is needed to fully understand underlying reasons and clinical implications, the IDI appears to be a valuable means of monitoring prescribing trends over time. En ligne : https://doi.org/10.1016/j.rasd.2020.101642 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=4331

Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences / Matthew J. F. EGGLESTON in Research in Autism Spectrum Disorders, 62 (June 2019) 

Public ISBD [article]  in Research in Autism Spectrum Disorders > 62 (June 2019) . - p.18-25 Titre : Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences Type de document : texte imprimé Auteurs : Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Christopher M. A. FRAMPTON, Auteur ; Katherine H. F. EGGLESTON, Auteur ; Shannon C. HENNIG, Auteur Article en page(s) : p.18-25 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Parent  Satisfaction  Diagnosis  Supports  Survey Index. décimale : PER Périodiques Résumé : Background This study explored New Zealand parents’ experiences of obtaining an autism spectrum disorder (ASD) diagnosis for their child and aimed to identify factors that predicted parent satisfaction. Method Parents of ASD parent support groups were invited by email to participate in an anonymous online survey. Parents were asked to rate their satisfaction with a number of key aspects of the diagnostic process for ASD. Correlation analysis and ANOVA were utilized to explore possible associations between parent satisfaction and putative demographic and clinical factors and experiences. Multiple regression analysis was used to identify key predictor variables of parent satisfaction and stress. Results Parent (n?=?516) satisfaction with the diagnostic process for ASD was endorsed by 53.1%. The strongest predictor was satisfaction with the diagnostic assessment report, followed by higher levels of parent stress. Higher satisfaction was also predicted by spending less time on a wait-list for assessment, multi-disciplinary assessment and the absence of concurrent ADHD. Most parents found the diagnostic process stressful. Only 23% of parents were satisfied with post-diagnostic supports, and just 19% their coordination. Conclusions Just over half of New Zealand parents are satisfied with the diagnostic process for ASD, despite most finding the process stressful. Streamlining referral pathways, reducing assessment wait-times and increasing rates of multi-disciplinary team assessment may raise satisfaction rates further. Receiving a satisfactory diagnostic assessment report appears to be of particular importance to parents. The very low rate of satisfaction with post-diagnostic supports indicates that further development of these services is a priority for NZ. En ligne : https://doi.org/10.1016/j.rasd.2019.02.004 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=3890 [article] Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences [texte imprimé] / Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Christopher M. A. FRAMPTON, Auteur ; Katherine H. F. EGGLESTON, Auteur ; Shannon C. HENNIG, Auteur . - p.18-25. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 62 (June 2019) . - p.18-25 Mots-clés : Autism spectrum disorder  Parent  Satisfaction  Diagnosis  Supports  Survey Index. décimale : PER Périodiques Résumé : Background This study explored New Zealand parents’ experiences of obtaining an autism spectrum disorder (ASD) diagnosis for their child and aimed to identify factors that predicted parent satisfaction. Method Parents of ASD parent support groups were invited by email to participate in an anonymous online survey. Parents were asked to rate their satisfaction with a number of key aspects of the diagnostic process for ASD. Correlation analysis and ANOVA were utilized to explore possible associations between parent satisfaction and putative demographic and clinical factors and experiences. Multiple regression analysis was used to identify key predictor variables of parent satisfaction and stress. Results Parent (n?=?516) satisfaction with the diagnostic process for ASD was endorsed by 53.1%. The strongest predictor was satisfaction with the diagnostic assessment report, followed by higher levels of parent stress. Higher satisfaction was also predicted by spending less time on a wait-list for assessment, multi-disciplinary assessment and the absence of concurrent ADHD. Most parents found the diagnostic process stressful. Only 23% of parents were satisfied with post-diagnostic supports, and just 19% their coordination. Conclusions Just over half of New Zealand parents are satisfied with the diagnostic process for ASD, despite most finding the process stressful. Streamlining referral pathways, reducing assessment wait-times and increasing rates of multi-disciplinary team assessment may raise satisfaction rates further. Receiving a satisfactory diagnostic assessment report appears to be of particular importance to parents. The very low rate of satisfaction with post-diagnostic supports indicates that further development of these services is a priority for NZ. En ligne : https://doi.org/10.1016/j.rasd.2019.02.004 Permalink : http://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=3890